WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating GeneDx Holdings Corp. for potential violations of securities laws, following allegations of widespread fraud as reported by Grizzly Research [1][2]. Group 1: Investigation Details - The investigation centers on whether GeneDx made false or misleading statements and failed to disclose critical information to investors [2]. - Grizzly Research's report claims that GeneDx's growth is largely fabricated, driven by fraudulent practices aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue [2]. - Allegations include that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet necessary criteria [2]. Group 2: Insider Trading Allegations - The report suggests that CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, indicating potential insider knowledge of imminent risks affecting the company [2]. - This pattern of behavior raises concerns about the integrity of the company's financial practices and the potential for significant impacts on its stock value [2].